Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register

Annals of the Rheumatic Diseases

Volumn 70, Issue 10, 2011, Pages 1810-1814

  Galloway, J B ^a   Hyrich, K L ^a   Mercer, L K ^a   Dixon, W G ^a   Ustianowski, A P ^b   Helbert, M ^c   Watson, K D ^a   Lunt, M ^a   Symmons, D P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTHROPLASTY; ARTICLE; BACTERIAL ARTHRITIS; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LISTERIOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OBSERVATIONAL STUDY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS INFECTION; PSEUDOMONAS INFECTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SALMONELLOSIS; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, INFECTIOUS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINT PROSTHESIS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSTHESIS-RELATED INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052458079     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.152769     Document Type: Article

References (23)

1. Gupta M.N., Sturrock R.D., Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford) 2001;40:24-30.
2. Weston V.C., Jones A.C., Bradbury N., et al. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. Ann Rheum Dis 1999;58;4:214-219 (Pubitemid 29191651)
3. Geirsson A.J., Statkevicius S., Vikingsson A. Septic arthritis in Iceland 1990-2002: Increasing incidence due to iatrogenic infections. Ann Rheum Dis 2008;67:638-643 (Pubitemid 351571927)
4. Favero M., Schiavon F., Riato L., et al. Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. Autoimmun Rev 2008;8:59-61.
5. Kaandorp C.J., Van Schaardenburg D., Krijnen P., et al. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 1995;38:1819-1825 (Pubitemid 26010283)
6. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-2293
7. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412 (Pubitemid 41612206)
8. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-1344 (Pubitemid 47492478)
9. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including sitespecifi c and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376 (Pubitemid 44204996)
10. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the BSRBR. Ann Rheum Dis 2010;69:522-528
11. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-744
12. Rachapalli S., O'Daunt S. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum 2005;52:987. (Pubitemid 40365125)
13. Katsarolis I., Tsiodras S., Panagopoulos P., et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005;37:304-305 (Pubitemid 40542779)
14. Elwood R.L., Pelszynski M.M., Corman L.I. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003;22:286-288 (Pubitemid 36351083)
15. National Institute for Health and Clinical Excellence. Rheumatoid Arthritis - Etanercept and Infliximab. London: NICE, 2001.
16. Hyrich K.L., Watson K.D., Isenberg D.A., et al. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 2008;47:1441-1443
17. Kirwan J.R., Reeback J.S. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-209 (Pubitemid 16033804)
18. Prevoo M.L., Van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
19. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-528
20. Curtis L.H., Hammill B.G., Eisenstein E.L., et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45 (10 Suppl 2):S103-S107
21. Hyrich K.L., Watson K.D., Lunt M., et al. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50:117-123
22. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-144 (Pubitemid 351339884)
23. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-163 (Pubitemid 40277395)